Autologous bone marrow mesenchymal cell induced chondrogenesis for the treatment of osteoarthritis of knee

Abstract

Healthy and high quality of life has become the main issue with increasing human life span. Many biological treatments for osteoarthritis of the knee have been tried with limited success. We compared data from 7 patients who underwent total knee arthroplasty and 46 patients who underwent autologous bone-marrow mesenchymal cell induced chondrogenesis (MCIC) for osteoarthritis of grade IV of the Kellgren-Lawrence classification and grade IV of modified Outerbridge classification from 50 to 65 years of age. Clinical evaluation of the 2 groups showed significant improvement in the mean telephone Knee Society Scoring system (tKSS)-A (pain) and tKSS-B (function) scores throughout the postoperative follow-up period. There was no difference in the patients' satisfaction between the 2 groups. MCIC is a treatment option at least for delaying disease progression of osteoarthritis of the knee.

Endogenous Stem Cells in Homeostasis and Aging

“…BMSCs have self-renewal capacity, mobilize to injury sites, and participate in immune modulation, wound [34][35][36][37]. The main physiological capacity of BMSCs is an immune modulatory function by releasing cytokines, which seems to be independent of traditional stem cell activity.…”

Neuroimmune modulation of pain and regenerative pain medicine

“…RCTs demonstrate effectiveness of MSCs as a stand-alone technique (139) and as part of a surgical procedure (140). Meta-analyses support the effectiveness of both approaches with noted variability of technique and cell sources (89,143).…”

“…A growing number of trials demonstrate favorable results for the use of MSCs in the treatment of osteoarthritis, including studies using cells derived from bone marrow (139,140), adipose tissue (141), and peripheral blood (142) (Table 3). The positive therapeutic impact of MSCs for the treatment of arthritis is supported by both recent systematic reviews and meta-analyses (89,143), although concerns about bias have been expressed (144).…”

“…Enthusiasm about the possibility of cartilage regrowth with MSC therapies was further inspired by demonstration that MSCs alleviated cartilage defects to a greater extent when added to surgical interventions such as microfracturing (145) or as an isolated nonsurgical procedure (146). As a result, MSC therapies are now commonly employed as a stand-alone procedure (143), or in conjunction with surgical repair, using bioengineered scaffolds to support cellular growth (140). A divergence between clinical effect and cartilage regrowth was observed in studies demonstrating improved function and pain despite persistent cartilage defects (147), implying that the analgesic benefits may result from nonregenerative mechanisms.…”

Mechanically Reinforced Extracellular Matrix Scaffold for Application of Cartilage Tissue Engineering

“…The limited blood supply in cartilage is thought to be responsible for its limited capacity for self-repair; thus, cartilage defect cannot be naturally regenerated. In particular, damaged cartilage may cause pain and disability; therefore, Numerous techniques have been developed to repair articular cartilage damage, a typical example being tissue engineering, a promising way to restore functional hyaline cartilage in joints [2,3].…”